Why is Aurobindo Pharma falling/rising?

As of 30-Jul, Aurobindo Pharma Ltd. is currently priced at 1,153.50, reflecting a decrease of 4.6 points or 0.4%. The stock has recently underperformed its sector by 0.74% and has experienced a trend reversal, falling after five consecutive days of gains. In terms of returns, the stock has shown a 3.42% increase over the past week, while it has gained 1.62% over the past month. However, it has a year-to-date decline of 13.61% and a one-year drop of 17.31%. Despite these declines, the company maintains a low debt-to-equity ratio and an attractive valuation, with a return on equity of 10.7 and a price-to-book value of 2.1, suggesting that it is trading at fair value compared to its peers.
In the broader market context, Aurobindo Pharma's recent performance contrasts with the benchmark Sensex, which has declined by 1.50% over the past week and 2.54% over the past month. The stock's liquidity appears adequate, with a delivery volume increase of 6.6% against the five-day average, and high institutional holdings at 41.31% indicate strong investor confidence. However, the stock's significant year-to-date and one-year declines suggest that broader market conditions may be impacting its performance, despite the company's rising profits and relatively stable fundamentals.